KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Capital Expenditures (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Capital Expenditures data on record, last reported at $3.6 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 90.57% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $102.0 million, down 25.54%, while the annual FY2025 figure was $102.0 million, 25.54% down from the prior year.
  • Capital Expenditures reached $3.6 million in Q4 2025 per SRPT's latest filing, down from $22.9 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $43.7 million in Q1 2025 and bottomed at $2.2 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $19.2 million, with a median of $18.5 million recorded in 2023.
  • Peak YoY movement for Capital Expenditures: crashed 92.29% in 2021, then soared 261.02% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $2.2 million in 2021, then skyrocketed by 261.02% to $8.0 million in 2022, then skyrocketed by 139.06% to $19.0 million in 2023, then skyrocketed by 100.02% to $38.1 million in 2024, then crashed by 90.57% to $3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $3.6 million in Q4 2025, $22.9 million in Q3 2025, and $31.8 million in Q2 2025.